Sichuan Kelun-Biotech’s SKB264/MK-2870 Approved by NMPA for Triple Negative Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990), a China-based biopharmaceutical company, has received market approval...
Fineline Cube
NHC Aims for Nationwide Inspection Result Sharing in Medical Consortia by 2030
The National Healthcare Commission (NHC) has issued the “Guiding Opinions on Further Promoting Mutual Recognition...
CORXEL’s Varenicline Nasal Spray Approved by NMPA for Dry Eye Treatment
Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, supported by RTW Investments, has received approval...
Arrowhead and Sarepta Seal $11.38 Billion Global Licensing Deal for Rare Disease Treatments
US-based companies Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) and Sarepta Therapeutics (NASDAQ: SRPT) have announced a...
Pfizer Partners with CR Pharma to Expand Cancer Drug Access in China
US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has entered into a strategic agreement with China...
Roche’s Evrysdi Receives Patent Term Extension in China, Extending Protection to 2035
The China National Intellectual Property Administration (CNIPA) has granted Swiss pharmaceutical giant Roche (SWX: ROG)...
CanSino Biologics’ Menhycia Vaccine Aims to Expand Age Range with NMPA Filing
CanSino Biologics (HKG: 6185) has announced that the National Medical Products Administration (NMPA) has accepted...
Jiangsu Hengrui Medicine’s SHR-1819 Receives NMPA Approval for Atopic Dermatitis Clinical Trial
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that it has received clinical trial...
AstraZeneca’s Truqap Meets Primary Endpoint in Phase III Prostate Cancer Study
UK-based pharmaceutical giant AstraZeneca Inc., (AZ, NASDAQ: AZN) has announced that its Phase III CAPItello-281...
Sichuan Huiyu Pharmaceutical’s HY-2003 Approved for Clinical Trials by China’s NMPA
Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that it...
J&J’s Stelara Faces New Biosimilar Competition in China with CSPC Pharmaceutical’s Entry
Johnson & Johnson (J&J, NYSE: JNJ)’s auto-immune disease drug Stelara (ustekinumab) is set to encounter...
AstraZeneca’s ALXN1850 (Efzimfotase Alfa) Selected for China’s Rare Disease Care Plan
The Center for Drug Evaluation (CDE) in China has announced its intention to include AstraZeneca’s...
Amgen’s MariTide Showcases Significant Weight Loss in Phase II Study
US biotechnology company Amgen (NASDAQ: AMGN) has announced positive outcomes from the double-blind, dose-ranging Phase...
VectorBuilder and Zhejiang Dapu Biotechnology Form Partnership to Advance Biotech Innovation
China-based gene delivery technology developer VectorBuilder has entered into a partnership with Zhejiang Dapu Biotechnology...
Roche’s SKYSCRAPER-01 Study: Tiragolumab-Tecentriq Combo Misses Primary Endpoint in NSCLC
Swiss pharmaceutical giant Roche (SWX: ROG) has reported an update on the phase III SKYSCRAPER-01...
Roche to Acquire Poseida Therapeutics in a USD 1.5 Billion Deal
US-based clinical-stage biopharmaceutical company, Poseida Therapeutics (NASDAQ: PSTX), which specializes in donor-derived CAR-T cell therapies,...
Zymeworks and Jazz Pharmaceuticals’ Ziihera Gets Green Light for HER2+ BTC Treatment
Partners Zymeworks Inc. (NASDAQ: ZYME) and Jazz Pharmaceuticals, Inc. have received accelerated approval from the...
Lakeside Holding’s Hupan Pharmaceutical Partners with Sinopharm Group Hubei for Supply Chain Services
US-based supply chain solution provider Lakeside Holding Limited (NASDAQ: LSH), which specializes in the Asian...
NHSA to Announce NRDL Adjustment Results at November 28th Press Conference
The National Healthcare Security Administration (NHSA) will unveil the results of the negotiation and price...
NMPA and Local Governments Streamline Drug Approval Processes in China
The National Medical Products Administration (NMPA) has released a notification regarding the pilot work for...